The Worldwide Male Hypogonadism Industry is Expected to Reach $5 Billion by 2030
Retrieved on:
Monday, October 24, 2022
Spermatozoon, Hypogonadism, FSH, Testosterone, Prevalence, Growth, Population, Diagnosis, Degenerative disease, GNRH, Klinefelter syndrome, CAGR, Bayer, Patient, Porter's five forces analysis, Man, Kallmann syndrome, Company, Obesity, Luteinizing hormone, Allergan, Awareness, Incidence, Diabetes, Ageing, Infertility, HCG, Benchmarking, Gonadotropin-releasing hormone, Pharmaceutical industry, Birth control, Retail, Male
The global male hypogonadism market was valued $ 3,072.86 million in 2020 and expected to reach $ 5,085.03 million by 2030, with a CAGR of 5.1% from 2021 to 2030.
Key Points:
- The global male hypogonadism market was valued $ 3,072.86 million in 2020 and expected to reach $ 5,085.03 million by 2030, with a CAGR of 5.1% from 2021 to 2030.
- It is caused owing to the disorder related to the testes (primary hypogonadism) or the hypothalamic-pituitary axis (secondary hypogonadism).
- The factors that drive the global male hypogonadism market are increase in cases of hypogonadism, surge in awareness of hypogonadism, and rise in number of treatment options.
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the male hypogonadism market analysis from 2020 to 2030 to identify the prevailing male hypogonadism market opportunities.